GLP-1 drugs before anesthesia
Should GLP-1 receptor agonists be continued or withheld before anesthesia? Compare residual gastric-content studies with actual aspiration outcomes, and distinguish elective surgery from endoscopy.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 36 of 87 · Other
Recent evidence · past year
-
A practical framework for using GLP-1 RAs, SGLT2i, and MRAs with contemporary immunosuppression in kidney transplant recipients.
AI summary of the abstract, unverified
- This is a narrative review presenting a practical framework for adding GLP-1 RAs, SGLT2 inhibitors, and MRAs to kidney transplant immunosuppression.
- The authors describe evidence in transplant recipients as limited, suggesting possible benefits for glycemia, weight, blood pressure, proteinuria, and cardiorenal risk without routine immunosuppression changes.
- Whether these agents improve patient or graft survival is unproven, and GLP-1 RA gastrointestinal effects may alter oral immunosuppressant absorption, warranting trough monitoring.
- The authors advise individualized, sequential introduction with monitoring of graft function, electrolytes, volume status, and immunosuppressant exposure, plus drug-specific sick-day and perioperative holds.
Original abstract (PubMed)
PURPOSE OF REVIEW: Calcineurin inhibitors (CNIs) remain central to kidney-transplant (KTX) immunosuppression (IS) but contribute to nephrotoxicity and cardiometabolic (CM) complications which negatively affect patient and graft survival. This review presents a practical framework for adding glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and mineralocorticoid receptor antagonists (MRAs) to established IS regimens. These agents complement individualized optimization of IS, including CNI-sparing strategies when indicated. RECENT FINDINGS: Evidence in KTX recipients remains limited, but available studies suggest that these agents may improve glycemic control, weight, blood pressure, proteinuria, and cardiorenal risk without routinely requiring changes to IS choice or dose. Whether these changes improve patient and graft survival remains unproven. GLP-1 RA related gastrointestinal effects may alter oral IS absorption, warranting continued CNI trough monitoring, particularly when significant gastrointestinal symptoms occur after initiation or dose escalation. SGLT2i require assessment of volume status, renal-function, and infection risk. MRAs may compound CNIs associated hyperkalemia and early eGFR decline, requiring close potassium and renal-function monitoring. SUMMARY: These therapies may extend cardiorenal benefits observed in nontransplant chronic kidney disease to selected KTX recipients. Their use should be individualized, introduced sequentially, and supported by monitoring of graft function, electrolytes, volume status, blood pressure, and IS exposure. Temporary withholding should follow drug-specific perioperative and sick-day guidance, particularly for SGLT2i.
-
Assessment of preoperative gastric content with ultrasound in patients taking GLP-1 receptor agonists: an observational, multicenter, cross-sectional study.
No abstract available in PubMed.
-
Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
AI summary of the abstract, unverified
- This is a clinical framework paper, not an empirical study, and it draws on patient scenarios from common geriatric contexts rather than reported trial data.
- It addresses gut-hormone obesity drugs (GLP-1, GLP-1/GIP, and emerging triple agonists) used in older adults, with attention to sarcopenia, frailty, dehydration, aspiration, and weight regain.
- The authors argue that lean mass loss, malnutrition, and perioperative aspiration may matter more in older adults and need closer monitoring.
- They propose framing prescribing within the Geriatrics 5Ms and pairing treatment with resistance training, adequate protein, and functional monitoring.
Original abstract (PubMed)
Obesity medications that act through gut-derived hormonal pathways include glucagon-like peptide-1 receptor agonists (GLP-1), dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GLP-1/GIP), and emerging triple glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor agonists. These therapies are increasingly prescribed for weight management and glycemic control, as well as for their cardiometabolic and renal benefits. While these medications offer substantial benefits to patients across multiple health conditions, their use in older adults warrants heightened scrutiny. Older adults face increased risks of sarcopenia and frailty, and evidence from major clinical trials suggests that a substantial proportion of medication-associated weight loss agents may result in loss of lean mass, potentially posing risks for this population. Other adverse effects that may be more consequential in older adults include dehydration, malnutrition, perioperative aspiration, and fat-predominant weight regain after discontinuation. This paper provides a clinically oriented framework to guide prescribing decisions for older adults. Drawing on patient scenarios from common geriatric contexts, including frailty, cognitive impairment, glucocorticoid use, and surgical planning, we propose prescribing approaches that optimize therapeutic benefits while mitigating potential harms. We integrate these recommendations within the Geriatrics 5Ms Framework (Mind, Mobility, Medications, Multicomplexity, and Matters Most) to contextualize treatment within geriatrics practice. Lifestyle co-interventions, particularly resistance training, adequate protein intake, and ongoing functional monitoring, emerge as essential components for older adults receiving these therapies. We also discuss identifying priority areas for future research, including age-stratified clinical trials and the routine inclusion of body composition and physical function outcomes.
-
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Post-Anesthetic Pulmonary and Gastrointestinal Adverse Events: A Target Trial Emulation Using Multinational Database.
AI summary of the abstract, unverified
- Target trial emulation using the TriNetX multinational database, with 21,948 propensity-matched adults aged 20 or older who underwent general anesthesia.
- Exposure was GLP-1 receptor agonist use before anesthesia versus no use, with one-month pulmonary and gastrointestinal adverse events analyzed by Cox regression.
- GLP-1 RA users had a lower risk of pulmonary adverse events (HR 0.682, 95% CI 0.496-0.938), with reduced respiratory failure and revisits also reported.
- Gastrointestinal adverse events were marginally higher with GLP-1 RA use (HR 1.034, 1.003-1.067); the authors describe this signal as modest.
Original abstract (PubMed)
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying, raising concerns about perioperative aspiration and postoperative complications. This target trial emulation aims to evaluate the association between the use of GLP-1 RAs and the risk of postoperative pulmonary and gastrointestinal adverse events in patients undergoing general anesthesia. METHODS: Data was utilized from the TriNetX Global Collaborative Network. The study analyzed data from January 1, 2023, to December 31, 2023. Patients aged 20 years or older who underwent general anesthesia were included. These patients were divided into two groups: those using GLP-1 RA and those who were not. Propensity score matching was used to balance baseline characteristics. The primary outcome measures were the incidence of pulmonary and gastrointestinal adverse events within one-month post-anesthesia. Hazard ratios were calculated using Cox proportional hazards regression models to estimate the risk of these adverse events associated with GLP-1 RA use. RESULTS: A total of 21,948 patients were included after matching. Patients who used GLP-1 RAs demonstrated a significantly lower risk of pulmonary adverse events (HR 0.682 [0.496-0.938]). Secondary outcomes further revealed a reduction in the risk of postoperative respiratory failure, as well as postoperative hospitalization and emergency department revisits. However, there was a marginally increased risk of gastrointestinal adverse events in the GLP-1 RA group (HR, 1.034 [1.003-1.067]). CONCLUSIONS: The use of GLP-1 RAs prior to general anesthesia was not associated with higher risk of pulmonary adverse events. A slight elevation in gastrointestinal risks was observed, although the signal remained modest.
-
Outcomes after Posterior Cervical Spine Surgery: A Matched Cohort Analysis and Comparison of GLP-1 Receptor Agonist Use and Bariatric Surgery in Patients with Type 2 Diabetes.
AI summary of the abstract, unverified
- Retrospective PearlDiver Mariner database study of patients with type 2 diabetes on metformin who underwent posterior cervical surgery from 2010 to 2023, using propensity-score matching.
- Preoperative GLP-1 receptor agonist users were compared with matched non-users and with patients who had prior bariatric surgery.
- GLP-1 users had lower odds of perioperative pneumonitis (OR 0.57; 95% CI 0.43-0.75; p<0.001) and of 90-day revision surgery (OR 0.33; 95% CI 0.29-0.36; p<0.001).
- Lower odds persisted for 2-year revision surgery and nutritional deficiency, and no significant differences were found versus the bariatric surgery cohort.
Original abstract (PubMed)
BACKGROUND CONTEXT: Obesity and diabetes can increase perioperative risk, especially in posterior cervical spine surgery. Bariatric surgery provides durable weight loss but carries surgical and nutritional risks, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are non-surgical alternatives that may optimize weight and metabolic status preoperatively. Evidence evaluating GLP-1 therapy in spine surgery is limited. PURPOSE: To evaluate associations between preoperative GLP-1 RA use and perioperative, short-term, and long-term complications following posterior cervical spine surgery in patients with type 2 diabetes, including comparisons to matched controls and patients with prior bariatric surgery. STUDY DESIGN: Retrospective database analysis. PATIENT SAMPLE: Patients with type 2 diabetes treated with metformin undergoing posterior cervical spine surgery between 2010 and 2023 were identified in the PearlDiver Mariner database. Patients were stratified into GLP-1 users, non-GLP-1 controls, and patients with prior bariatric surgery. OUTCOME MEASURES: Physiologic measures included perioperative outcomes and postoperative complications assessed at 90 days and 2 years, including pneumonitis, surgical site infection, revision surgery, readmission, nutritional deficiency, and other medical and surgical complications. METHODS: The PearlDiver Mariner database was queried for eligible patients. Propensity-score matching adjusted for baseline cohort differences. Outcomes included perioperative, 90-day, and 2-year complications, with BMI-stratified analyses conducted within the matched GLP-1 and control cohort. Benjamini-Hochberg false discovery rate correction was applied for multiple comparisons. RESULTS: GLP-1 users demonstrated lower odds of perioperative complications, including pneumonitis (OR 0.57; 95% CI 0.43-0.75; p <0.001). At 90 days, GLP-1 users experienced reduced odds of surgical site infection (OR 0.72; 95% CI 0.65-0.80; p <0.001), revision surgery (OR 0.33; 95% CI 0.29-0.36; p <0.001), readmission (OR 0.82; 95% CI 0.76-0.90; p <0.001), and other complications. At 2 years, GLP-1 users had lower odds of revision surgery (OR 0.31; 95% CI 0.28-0.34; p <0.001), nutritional deficiency (OR 0.62; 95% CI 0.59-0.66; p <0.001), and other complications. Exploratory BMI-stratified analyses suggested similar directional trends across overweight and obese patients. Comparisons to prior bariatric surgery patients showed no significant differences. CONCLUSIONS: Preoperative GLP-1 RA use was associated with reduced perioperative, short-term, and long-term complications following posterior cervical spine surgery in patients with type 2 diabetes. When compared with a matched bariatric surgery cohort, no significant differences in postoperative outcomes were observed. These findings should be interpreted in the context of potential residual confounding and support further prospective investigation of GLP-1 therapy as a strategy for preoperative metabolic optimization in posterior cervical spine surgery. CLASSIFICATIONS: Cervical Spine, Outcomes Research, Risk Factors, Perioperative Complications.
-
Navigating Electroconvulsive Therapy in Patients on GLP-1 Receptor Agonists: Balancing Safety, Compliance, and Treatment Consistency: A Case Report.
AI summary of the abstract, unverified
- This case report describes one patient with refractory major depressive disorder taking tirzepatide, a GLP-1 receptor agonist, who received ECT.
- ECT and anesthesia leadership developed a novel pre-ECT fasting protocol for GLP-1 RA users, as an alternative to a 24-hour clear-liquid diet or frequent rapid sequence intubations.
- The patient completed 17 ECT treatments without complications.
- The authors frame the protocol as a way to balance aspiration safety, patient compliance, and treatment consistency.
Original abstract (PubMed)
Electroconvulsive therapy (ECT) is typically performed under general anesthesia without a secured airway, placing patients with retained gastric contents at increased risk of aspiration. As more patients present for ECT while taking GLP-1 receptor agonists, standard fasting requirements pose unique safety and patient-experience challenges. A 24-hour clear-liquid diet every other day is burdensome, while frequent rapid sequence intubations may prolong treatment and recovery. To address this, ECT and anesthesia leadership developed a novel pre-ECT fasting protocol for patients on GLP-1 RAs. We report a patient with refractory major depressive disorder on tirzepatide who successfully completed 17 ECT treatments without complications.
-
Effects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary review.
AI summary of the abstract, unverified
- This contemporary narrative review combined a targeted PubMed/MEDLINE search from 2015 onward with manual reference screening, including cohorts, database analyses, surveys, and case reports.
- It examines how GLP-1 receptor agonists affect aesthetic surgery demand and outcomes across facial, breast, and body contouring procedures.
- The authors argue that facial volume loss and skin laxity ('Ozempic face') more plausibly reflect rapid or substantial weight loss than a proven drug-specific facial effect.
- Body contouring outcomes are heterogeneous, with some studies reporting comparable complications and others noting delayed healing or dehiscence; the authors call for individualized decisions and prospective studies.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly relevant to aesthetic surgery because of the significant weight loss they provide in the treatment of type 2 diabetes mellitus and obesity. While these agents expand the pool of surgical candidates, they also raise new clinical questions related to rapid or substantial weight loss, including soft tissue volume loss, skin laxity, nutritional deficiencies, perioperative safety concerns, and the durability of aesthetic surgical outcomes. This contemporary narrative review evaluated the current implications of GLP-1 RAs in aesthetic plastic surgery practice. A targeted PubMed/MEDLINE search covering January 2015 through August 2026 was supplemented by manual reference screening. Retrospective cohorts, database analyses, prospective observational studies, systematic reviews, survey studies, case reports, and selected guidance or opinion articles were evaluated. Current literature indicates increasing demand for facial aesthetic, breast aesthetic, and body contouring procedures among patients using GLP-1 RAs. The facial volume loss and skin laxity popularly described as "Ozempic face" more plausibly reflect rapid or substantial weight loss than a proven drug-specific facial effect. Although the breast surgery literature remains limited, upper-pole volume loss, ptosis, reduced soft tissue support, and healing problems along high-tension closure lines are noteworthy. Outcomes in body contouring surgery are heterogeneous: While some studies report comparable complication rates, others emphasize delayed wound healing, wound dehiscence, altered scar behavior, or nutrition-related risks. Surgical timing, weight stabilization, nutritional balance, and individualized perioperative aspiration-risk assessment are key areas of evaluation. GLP-1 RA use should be considered neither an absolute advantage nor an automatic contraindication in aesthetic surgery. Direct pharmacologic effects often cannot be separated from the consequences of weight loss or baseline metabolic risk. Surgical decision-making should be individualized based on weight stability, metabolic optimization, nutritional status, history of bariatric surgery, psychological adaptation, and procedure-specific risks. Current evidence is promising but heterogeneous, and prospective studies are needed to clarify long-term aesthetic outcomes and procedure-specific risks.
-
Gastric residual volume in patients with obesity receiving GLP-1 receptor agonists: A comparative gastric ultrasound pilot study.
AI summary of the abstract, unverified
- Comparative cross-sectional pilot study of patients with obesity, comparing those taking GLP-1 receptor agonists with nonusers scheduled for surgery.
- Gastric point-of-care ultrasound in supine and lateral positions, with antral cross-sectional area and residual volume estimated by validated mathematical models.
- GLP-1 receptor agonist users had higher estimated gastric residual volume, and a higher proportion met ultrasound criteria for a full stomach; the abstract reports no effect sizes or p values.
- The authors conclude GLP-1 receptor agonist use was associated with a larger antrum and greater gastric contents, suggesting higher estimated aspiration risk, and propose ultrasound to guide individualized aspiration precautions.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) enhance insulin secretion, suppress glucagon release, promote satiety, and may slow gastric emptying. Introduced in 2005 for the treatment of type 2 diabetes and obesity, these agents have prompted interest in assessing delayed gastric emptying as a potential biomarker to predict treatment response and to guide decisions regarding long-term therapy. Point-of-care gastric ultrasound (POCUS) offers a bedside method to assess gastric contents. OBJECTIVES: To compare gastric residual volume (GRV) on gastric ultrasound among patients with obesity receiving GLP-1 RAs and nonusers and those with prior weight loss surgeries. METHODS: In this comparative cross-sectional pilot study, gastric POCUS was done on patients with obesity who took GLP-1 RAs and other patients with obesity with no history of taking GLP-1 RAs prior to surgery in the supine and lateral decubitus positions. Antral cross-sectional area and GRV were measured using validated mathematical models. RESULTS: Patients receiving GLP-1 RAs demonstrated higher estimated GRV compared with nonusers. A higher proportion of GLP-1 RA users met ultrasound criteria for a full stomach. CONCLUSION: Among patients with obesity, GLP-1 RA therapy was associated with enlargement of the gastric antrum, increased gastric volume, and greater residual gastric contents, leading to an elevated estimated risk of aspiration. This increased risk is primarily determined by gastric ultrasound findings rather than patient characteristics, comorbidities, or duration of treatment. Gastric ultrasound may support individualized perioperative decision-making regarding aspiration precautions.
-
Preoperative Glucagon-like Peptide-1 Receptor Agonists and Postoperative Outcomes: An Observational Analysis.
AI summary of the abstract, unverified
- An observational analysis of TriNetX electronic health record data (2013–2023) compared adults with type 2 diabetes who had anesthesia, propensity-matched 1:1.
- Preoperative GLP-1 receptor agonist use was compared with metformin, SGLT2 inhibitors, or DPP4 inhibitors, with outcomes assessed over 14 days after surgery.
- Versus metformin, GLP-1 RA use was associated with lower 14-day mortality (0.98% vs 2.20%; RR 0.44, 95% CI 0.31 to 0.64; Padj 0.0002).
- Versus DPP4 inhibitors, GLP-1 RAs were linked to lower mortality and bacterial pneumonia, while the SGLT2 inhibitor comparison for major adverse cardiovascular events was not significant.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes management with demonstrated benefits on glycemic control, cardiac outcomes, and weight reduction, but further study is needed to establish the impact of GLP-1 RAs on perioperative outcomes. METHODS: The authors conducted an observational analysis with data between June 1, 2013, to June 1, 2023, using an electronic health record database (TriNetX Research Network) before the 2023 American Society of Anesthesiologists guidance to hold GLP-1 RAs preoperatively. Adult surgical patients with type 2 diabetes mellitus having anesthesia were propensity-score-matched 1:1 by surgery type, patient characteristics, diabetic biomarkers, and risk factors for postoperative morbidity. The study compared GLP-1 RA use with (1) metformin, (2) sodium-glucose cotransporter 2 inhibitors, or (3) dipeptidyl peptidase-4 inhibitors (DPP4i). Each group did not have concomitant use of the comparator. Outcomes were 14-day postoperative mortality, aspiration pneumonitis, bacterial pneumonia, emergency intubation, acute kidney injury, stroke, acute myocardial infarction, and major adverse cardiovascular events as defined by a composite of mortality, myocardial infarction, or stroke. RESULTS: Preoperative GLP-1 RA use was associated with reduced mortality (0.98% vs . 2.20%; risk ratio [RR], 0.44; 95% CI, 0.31 to 0.64; Padj = 0.0002) when compared with metformin use. Compared with sodium-glucose cotransporter 2 inhibitors, GLP-1 RAs were associated with numerical difference in major adverse cardiovascular events (3.86% vs . 5.03%; RR, 0.77; 95% CI, 0.60 to 0.98; Padj = 0.13). When compared with DPP4is, GLP-1 RAs were associated with decreased postoperative mortality (1.84% vs . 2.89%; RR, 0.63; 95% CI, 0.45 to 0.89; Padj = 0.04) and bacterial pneumonia (0.85% vs . 1.80%; RR, 0.47; 95% CI, 0.29 to 0.76; Padj = 0.02). CONCLUSIONS: Preoperative GLP-1 RA use was associated with lower short-term postoperative mortality and reduced morbidity compared with metformin and DPP4is, and no increased aspiration risk compared with any other drug class. Although these findings suggest perioperative benefits of GLP-1 RAs, confirmation in prospective studies is needed to guide evidence-based management strategies.
-
Improving Patient Outcomes by Bridging Bariatric and Body Contouring Surgery with Comprehensive Prehabilitation.
AI summary of the abstract, unverified
- This is a narrative review of the literature on strategies to optimize outcomes in patients having bariatric and body contouring surgery, with no pooled sample.
- It examines exercise preconditioning, nutritional supplementation, psychological support, and modification of wound healing risk factors as a longitudinal prehabilitation approach.
- The authors report that these measures may improve cardiorespiratory fitness, and that prehabilitation may also support weight-loss durability, body composition, and candidacy for body contouring.
- They conclude that prehabilitation may optimize these patients, but standardized protocols and proof of effectiveness in this population still need further research.
Original abstract (PubMed)
BACKGROUND: Rates of obesity and diabetes are increasing in the United States, accompanied by greater use of bariatric surgery and pharmacologic therapies, including glucagon-like peptide-1 receptor agonists and glucose-dependent insulinotropic polypeptide-based agents. Although massive weight loss may improve glycemic control and blood pressure, patients seeking body contouring surgery remain medically complex. Reduced fat-free mass associated with weight-loss pharmacotherapy and the high incidence of wound healing complications after excess skin resection present additional perioperative challenges. METHODS: We reviewed the growing literature on strategies to optimize outcomes after body contouring surgery, with particular attention to exercise preconditioning, nutritional supplementation, psychological support, and modification of established wound healing risk factors. RESULTS: Current evidence suggests that supplementing conventional risk-factor modification with exercise preconditioning, nutritional support, and psychological interventions improve the cardiorespiratory fitness of weight loss patients. Comprehensive prehabilitation initiated before bariatric surgery and continued throughout weight loss and subsequent plastic surgical treatment may also improve weight-loss durability, body composition, and candidacy for body contouring. CONCLUSIONS: Prehabilitation may provide a comprehensive, longitudinal approach to optimizing patients undergoing bariatric and body contouring surgery. Integrating exercise, nutritional supplementation, psychological support, and traditional risk-factor modification has the potential to improve surgical candidacy, perioperative health, and postoperative outcomes. Further research is needed to define standardized protocols and determine their effectiveness in this population.
-
Prehabilitation for Aesthetic Surgery: An Evidence-based Guide.
AI summary of the abstract, unverified
- This narrative review covers medical management, nutrition, substance cessation, weight, and psychological factors in aesthetic surgery, with added detail for rhytidectomy and rhinoplasty.
- It notes that malnutrition, diabetes, and tobacco use are linked to adverse surgical outcomes, though aesthetic-specific recommendations for these are lacking.
- The authors advise addressing hypertension before rhytidectomy and obstructive sleep apnea before rhinoplasty, and considering psychological concerns from the initial consultation.
- They also state that GLP-1 agonists have changed the aesthetic landscape and that patients should be counseled on their use using the latest evidence.
Original abstract (PubMed)
BACKGROUND: Despite the growing number of aesthetic plastic surgery procedures performed annually and increasing emphasis placed on surgical prehabilitation to improve postoperative outcomes, there is not yet a standardized guide for patients undergoing these aesthetic procedures. The aim of this review is to identify the major components of prehabilitation for aesthetic surgery to decrease the risk of perioperative complications and facilitate a smooth recovery process. METHODS: A narrative literature review was conducted for common aesthetic surgery topics, including medical management, nutrition and diet, substance use cessation, weight management, and psychological factors surrounding aesthetic surgery. Additional information was included for specific procedures with existing robust evidence, including rhytidectomy and rhinoplasty. RESULTS: There are strong existing ties between established risk factors such as malnutrition, diabetes, and tobacco use with adverse surgical outcomes, though these topics lack aesthetic surgery-specific recommendations. Hypertension and obstructive sleep apnea should be addressed and managed for patients seeking rhytidectomy or rhinoplasty, respectively. Psychological concerns are pervasive among aesthetic surgery patients and should be kept in consideration beginning at the initial consultation. Emerging players, such as glucagon-like peptide-1 agonists, have shifted the aesthetic landscape, and patients should be counseled on their use with the latest evidence-based recommendations. CONCLUSIONS: Prehabilitation in aesthetic surgery should address known risk factors early on in surgical planning to prevent poor outcomes and should be tailored to each patient. There are certain measures, outlined here, that patients undergoing aesthetic surgery can take to prepare themselves for improved surgical outcomes and recovery.
-
[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects].
AI summary of the abstract, unverified
- Narrative review of a PubMed search (2020–2026) covering GLP-1 receptor agonists across urology and andrology domains.
- Agents discussed include semaglutide, liraglutide and tirzepatide, with domains spanning erectile dysfunction, hypogonadism, fertility, nephroprotection, prostate cancer and bladder symptoms.
- Benefits include better testosterone and erectile function in obesity-related hypogonadism, while semaglutide showed a 4.5-fold higher new-onset erectile dysfunction risk in non-diabetic obese men.
- The authors call these agents both an opportunity and a challenge, recommend systematic monitoring, and call for prospective controlled trials with urological endpoints.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have evolved rapidly from an antidiabetic drug class into one of the most influential pharmacological groups in internal medicine. The approved agents - semaglutide, liraglutide and the dual GIP/GLP-1 agonist tirzepatide - achieve weight reductions of up to 22% of body weight. The close pathophysiological link between obesity, metabolic syndrome and urological-andrological disease creates direct clinical relevance for urology.This narrative review summarises a systematic PubMed search (2020-2026) covering erectile dysfunction, hypogonadism, male fertility, nephroprotection, prostate cancer, lower urinary tract symptoms and perioperative considerations in the context of GLP-1 RA therapy.GLP-1 RAs show clinically relevant effects in several urological domains: increase in total testosterone and improvement in erectile function in men with obesity-related hypogonadism, nephroprotection with reduction of albuminuria and slowing of eGFR decline, signals of reduced prostate cancer risk in epidemiological studies, and indirect benefit for stress incontinence and overactive bladder via weight loss. At the same time, clinically relevant warning signals exist: a 4.5-fold increased risk of new-onset erectile dysfunction in non-diabetic obese men on semaglutide, novel urological adverse effects in case reports, perioperative aspiration risk through delayed gastric emptying, and a near-complete absence of data in women.GLP-1 RAs represent both a therapeutic opportunity and a clinical challenge for urologists. Systematic andrological and nephrological monitoring as well as proactive patient education on urogenital and perioperative implications is recommended. Prospective controlled trials with urological endpoints are needed.
-
Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study.
AI summary of the abstract, unverified
- National prospective multicentre cohort of 47,039 adults across 119 UK sites, undergoing anaesthetist-led procedures and screened for GLP-1 RA use in the prior 3 months.
- GLP-1 RA use was reported by 1348 patients (2.9%), and their peri-operative drug cessation and airway management varied considerably.
- Pulmonary aspiration and/or regurgitation occurred in 1.41% (95% CI 0.85-2.19%) of GLP-1 RA patients versus 0.12% (0.09-0.16%) of others; OR 11.39 (6.47-20.05), p<0.001.
- In the GLP-1 RA group, events most often happened during emergence from anaesthesia, with an overall incidence of about 1 in 71.
Original abstract (PubMed)
INTRODUCTION: Peri-operative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with delayed gastric emptying. It is unclear what proportion of patients having anaesthetic care are receiving GLP-1 RAs; what strategies are used in their peri-operative management; and whether the incidence of pulmonary aspiration and/or regurgitation is greater in this population. METHODS: We performed a national prospective multicentre cohort study of adults undergoing elective or emergency procedures under the care of an anaesthetist. Patients were screened for GLP-1 RA use in the 3 months before the index procedure. Data were collected on patient, procedure, anaesthesia and outcomes, including pulmonary aspiration and regurgitation. The primary outcome was the proportion of patients receiving GLP-1 RAs. Secondary outcomes described the pre-operative management of GLP-1 RAs; anaesthesia and airway management in patients receiving GLP-1 RAs; and the incidence of pulmonary aspiration and/or regurgitation. RESULTS: Of 47,039 patients from 119 sites across the UK, 1348 (2.9%) reported receiving GLP-1 RAs. Peri-operative management was variable regarding drug cessation, anaesthesia and airway management. The incidence (95%CI) of pulmonary aspiration and/or regurgitation in the non-GLP-1 RA cohort was 57/45,691 (0.12% (0.09-0.16%)) and in the GLP-1 RA cohort was 19/1348 (1.41% (0.85-2.19%)); odds ratio (95%CI) 11.39 (6.47-20.05), p < 0.001. In patients receiving GLP-1 RAs, pulmonary aspiration and/or regurgitation occurred most frequently during emergence from anaesthesia. DISCUSSION: In this national study, 1 in 36 patients undergoing anaesthesia care received GLP-1 RAs, and their peri-operative management was variable. A range of airway management techniques aiming to reduce pulmonary aspiration risk were observed but, despite this, the incidence of pulmonary aspiration and/or regurgitation was 1 in 71 in people receiving GLP-1 RAs.
-
Predictors of Perioperative Major Adverse Cardiovascular Events After Bariatric Surgery.
AI summary of the abstract, unverified
- Registry analysis of 1,095,255 adults undergoing primary sleeve gastrectomy or Roux-en-Y gastric bypass in MBSAQIP from 2019 to 2024.
- Thirty-day MACCE occurred in 1,368 patients (0.12%) and was more frequent after gastric bypass than after sleeve gastrectomy.
- Independent predictors included dialysis dependence, prior myocardial infarction, prior pulmonary embolism, male sex, insulin-dependent diabetes, and antihypertensive burden, with heart failure also associated in a subset.
- The authors conclude that risk reflects advanced systemic disease severity more than common comorbidities alone, and they advise prioritizing end-organ disease, insulin dependence, resistant hypertension, and established cardiovascular disease in preoperative evaluation.
Original abstract (PubMed)
Perioperative major adverse cardiac and cerebrovascular events (MACCE) after metabolic and bariatric surgery are uncommon but clinically important, particularly as the profile of patients undergoing surgery evolves in the era of expanded glucagon-like peptide-1 receptor agonist use. We analyzed adults undergoing primary laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program registry from 2019 to 2024 to determine the contemporary incidence of 30-day MACCE and identify independent predictors of risk. Among 1,095,255 patients, 1,368 experienced a 30-day major adverse cardiac or cerebrovascular event, corresponding to an incidence of 0.12%. Events were more frequent after Roux-en-Y gastric bypass than sleeve gastrectomy. In multivariable analysis, the strongest independent predictors included dialysis dependence, previous myocardial infarction, previous pulmonary embolism, male sex, insulin-dependent diabetes, and greater antihypertensive medication burden. Each additional antihypertensive medication was associated with higher odds of perioperative events, supporting treatment intensity as a marker of cardiometabolic disease severity. In a subset with available heart failure data, heart failure was also independently associated with increased risk. These findings suggest that perioperative cardiovascular risk after metabolic and bariatric surgery is driven less by the presence of common comorbidities alone and more by markers of advanced systemic disease severity. Contemporary preoperative evaluation should prioritize patients with end-organ disease, insulin dependence, resistant hypertension, and established cardiovascular disease to guide optimization and individualized perioperative risk assessment.
-
Preoperative GLP-1 receptor agonist use and outcomes after total hip arthroplasty: a matched cohort study.
AI summary of the abstract, unverified
- Matched cohort study using TriNetX data, with 1262 propensity-matched adults per group undergoing primary THA from 2003 to 2023.
- Patients with at least three GLP-1 receptor agonist prescriptions within one year before surgery were compared with matched controls.
- At 90 days, GLP-1 RA users had lower DVT (1.6% vs 3.0%; RR 0.53, 95% CI 0.31-0.89; p=0.014) and readmission (1.1% vs 2.8%; RR 0.40, 95% CI 0.22-0.71; p=0.001).
- No significant differences were seen in other 90-day outcomes or in 5-year mechanical outcomes, such as PJI and all-cause revision survival.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among total hip arthroplasty (THA) candidates, yet their perioperative impact remains unclear. METHODS: Using TriNetX, we identified adults undergoing primary THA (2003-2023) with preoperative GLP-1 RA exposure (⩾3 prescriptions within 1 year of surgery) versus controls. 1:1 propensity score matching for demographics, comorbidities, and baseline labs yielded 1262 patients per cohort. Outcomes included 90-day medical complications and mechanical complications (PJI, dislocation, aseptic loosening, periprosthetic fracture, all-cause revision) at 1, 2, and 5 years, reported in accordance with the STROBE guidelines. RESULTS: At 90 days, the GLP-1 RA cohort demonstrated significantly lower risks of DVT (1.6% vs. 3.0%; RR 0.53, 95% CI, 0.31-0.89; p = 0.014) and hospital readmission (1.1% vs. 2.8%; RR 0.40, 95% CI, 0.22-0.71; p = 0.001). No significant differences were found in other 90-day outcomes or in mechanical complications, including all-cause revision (94.6% vs. 95.5% survival; p = 0.674) and PJI (94.7% vs. 94.4%; p = 0.465) at 5 years. CONCLUSIONS: Consistent preoperative GLP-1 RA use is associated with reduced 90-day DVT and readmission following primary THA without increased risk of other complications or mechanical outcomes at 5 years. As DVT was the only significant thromboembolic endpoint, prospective investigation is needed before attributing a thromboprophylactic effect to these agents.
-
Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty.
AI summary of the abstract, unverified
- This database study matched 462 obese, non-diabetic GLP-1 users 1:10 to 4,377 non-users undergoing shoulder arthroplasty, using PearlDiver data from 2010 to 2023.
- GLP-1 users were compared with matched non-users on 90-day and 2-year outcomes after anatomic or reverse total shoulder arthroplasty.
- At 90 days, GLP-1 users had higher readmission (OR 2.034; 95% CI 1.594-2.578; P < .001) and overall complication rates (OR 1.474; 95% CI 1.295-1.799; P < .001).
- No differences were seen at 2 years for prosthetic joint infection, fracture, or all-cause revision, and the authors suggest perioperative GLP-1 use may be reasonable while readmissions warrant intervention.
Original abstract (PubMed)
BACKGROUND: Initially indicated for diabetes mellitus (DM), glucagon-like peptide 1 (GLP-1) agonists are now indicated for obesity management in isolation of DM. While prior studies have examined post-operative outcomes after total shoulder arthroplasty (TSA) in GLP-1 users with DM, there is a paucity of literature evaluating its use in non-diabetic patients for weight loss rather than glucose control. Therefore, our analysis compared 90-day and 2-year outcomes following TSA between non-diabetic obese GLP-1 users and a matched cohort of obese GLP-1 non-users. METHODS: The PearlDiver Mariner database was queried to identify patients who underwent anatomic TSA and reverse TSA between 2010 and 2023. Patients with a history of DM or who underwent TSA for cancer, infection, or pathologic fractures were excluded. Patients with a body mass index ≥ 30 kg/m2 within 6 months of surgery were included. GLP-1 users (within 3 months of surgery) were matched in a 1:10 ratio to GLP-1 non-users by age, sex, Elixhauser Comorbidity Index, smoking status, and various comorbidities. Multivariate logistic regression models were utilized to compare outcomes at 90 days and 2 years. RESULTS: After matching, 462 GLP-1 users and 4,377 GLP-1 non-users were included in our analysis. GLP-1 users had higher readmission rates (odds ratio: 2.034; 95% confidence interval: 1.594-2.578; P < .001) and subsequently overall complication rates (odds ratio: 1.474; 95% confidence interval: 1.295-1.799; P < .001) compared to GLP-1 non-users at 90 days. However, no differences were seen between cohorts for the remaining 90-day outcomes nor for all evaluated 2-year outcomes including prosthetic joint infection, fracture, and all-cause revision. DISCUSSION: Our analysis found a higher incidence of overall complications at 90 days among obese, non-diabetic GLP-1 users, driven largely by an increased incidence of readmissions. However, there were largely comparable outcomes at 2 years. These findings suggest that while GLP-1 agonists may be reasonable to use in the perioperative period, interventions to reduce readmissions among these patients may be warranted.
-
Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.
AI summary of the abstract, unverified
- Retrospective comparative observational study of 196 patients (98 per group) undergoing high-definition lipoabdominoplasty under general anesthesia.
- Group A received semaglutide or tirzepatide, while Group B received no GLP-1 receptor agonist therapy.
- No statistically significant between-group differences were found in intraoperative adverse events, recovery times, nausea and vomiting, pain scores, or early complications; the abstract gives no effect sizes or p values.
- The authors state these null findings do not show equivalence, since the study was not designed for non-inferiority testing and may be underpowered for rare events.
Original abstract (PubMed)
INTRODUCTION: The increasing use of glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) for pharmacological weight loss has led to a growing number of patients undergoing body-contouring procedures after rapid weight reduction. Given their effects on gastric emptying, metabolism, and nutritional status, concerns have been raised regarding potential implications for anesthetic management and perioperative safety. However, clinical data addressing anesthetic outcomes in this population remain limited. METHODS: This retrospective comparative observational study included patients undergoing highdefinition lipoabdominoplasty under general anesthesia. Group A consisted of patients receiving GLP-1 receptor agonists (semaglutide or tirzepatide), while Group B included patients not receiving such therapy. All patients underwent standardized preoperative assessment and surgical management. Primary outcomes were intraoperative adverse events, including respiratory complications, hemodynamic instability, and arrhythmias. Secondary outcomes included perioperative parameters (anesthesia and surgical duration, intraoperative EtCO₂ and SpO₂), recovery metrics (time to awakening, mobilization, and discharge), and early postoperative complications. Statistical comparisons were performed using appropriate parametric and non-parametric tests. RESULTS: A total of 196 patients were included (98 per group). No statistically significant Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation differences were observed between groups in demographic or baseline characteristics. Intraoperative parameters remained stable in both groups, with no clinically relevant respiratory events reported. Recovery profiles showed similar trends, with comparable times to awakening, mobilization, and discharge. The incidence of postoperative nausea and vomiting, pain scores, and early complications (seroma, infection, delayed wound healing, and hyperpigmentation) did not differ significantly between groups. DISCUSSION: Within the limitations of this study, no statistically significant differences were observed between patients receiving GLP-1 receptor agonists and controls in terms of intraoperative stability, recovery profile, and early postoperative outcomes. CONCLUSION: These findings should not be interpreted as evidence of equivalence, as the study was not designed for non-inferiority or equivalence testing and may be underpowered for rare events. Further prospective studies with larger sample sizes and stratification by specific GLP-1 receptor agonists are warranted. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
-
The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repair.
AI summary of the abstract, unverified
- Retrospective TriNetX cohort of 5,876 adults with type II diabetes undergoing rotator cuff repair from 2018 to 2024, including 233 preoperative GLP-1 agonist users.
- Compared preoperative GLP-1 agonist exposure with non-exposure for 90-day medical, surgical, and healthcare utilization outcomes, using unadjusted and inverse propensity score-weighted logistic regression.
- Unadjusted analyses showed higher odds of respiratory complications (OR 1.97, 95% CI 1.32-2.86), UTI (OR 3.85), and stiffness (OR 2.20); after weighting, no significant differences.
- The authors found no independent association between GLP-1 use and complication risk and suggest perioperative continuation may be safe, while calling for prospective studies.
Original abstract (PubMed)
BACKGROUND: Patients with type II diabetes mellitus (T2DM) undergoing rotator cuff repair (RCR) have increased postoperative risk. Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used in T2DM, but their perioperative safety remains uncertain. This study evaluated the association between preoperative GLP-1 agonist exposure and postoperative outcomes following RCR. METHODS: A retrospective cohort study using the TriNetX Research Network identified adults with T2DM undergoing RCR between 2018 and 2024. Patients were stratified by preoperative GLP-1 agonist exposure. Outcomes included 90-day medical complications, surgical complications, and healthcare utilization. Univariate and inverse propensity score-weighted binary logistic regression were performed to adjust for confounding. RESULTS: Among 5876 patients, 233 used GLP-1 preoperatively. Unadjusted analyses revealed increased odds of postoperative respiratory complications (odds ratio (OR): 1.97, 95% confidence interval (CI): 1.32-2.86, P = 0.0006), urinary tract infection (OR: 3.85, 95% CI: 1.31-9.12, P = 0.0055), and postoperative stiffness (OR: 2.20, 95% Cl: 1.31-3.49, P = 0.0016) among GLP-1 users. After inverse propensity score-weighting, no significant differences in postoperative outcomes were observed. DISCUSSION: Preoperative GLP-1 agonist use was not independently associated with decreased or increased risk of postoperative complications following RCR. These findings suggest perioperative continuation of GLP-1 therapy may be safe, though prospective studies are warranted.
-
Impact of GLP-1 dose intensity on perioperative and long-term fusion outcomes following ACDF.
AI summary of the abstract, unverified
- Retrospective TriNetX cohort of adults undergoing ACDF; the primary high-dose versus standard-dose comparison included 921 propensity-matched patients per arm.
- Exposure was the GLP-1 receptor agonist prescription strength recorded from 1 year to 1 week before surgery, comparing high-dose with standard-dose use.
- Ninety-day readmission was 11.4% versus 10.0% (p=.327), and opioid exposure was 85.2% versus 83.1% (p=.202), with no significant differences in complications or fusion outcomes.
- Both standard-dose and high-dose users had lower pseudarthrosis rates than nonusers, but higher dose added no further long-term benefit, and the authors conclude high-dose therapy does not add perioperative or fusion risk.
Original abstract (PubMed)
BACKGROUND CONTEXT: High-dose glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for obesity management, but their perioperative safety and potential effects on fusion-related outcomes after anterior cervical discectomy and fusion (ACDF) remain unclear. PURPOSE: To compare short-term postoperative outcomes and longer-term fusion-related outcomes after ACDF among patients receiving high-dose versus standard-dose GLP-1 RA therapy. STUDY DESIGN/SETTING: Retrospective cohort study using the TriNetX Research Network. PATIENT SAMPLE: Adult patients undergoing ACDF were identified within TriNetX and stratified into 3 pairwise comparison groups: standard-dose GLP-1 RA versus no GLP-1 exposure, high-dose GLP-1 RA versus no GLP-1 exposure, and high-dose versus standard-dose GLP-1 RA use. A total of 112,065 patients met inclusion criteria across all 3 comparisons. In the primary dose-intensity comparison, 921 patients remained in each cohort after 1:1 propensity score matching. OUTCOME MEASURES: Outcomes included 90-day healthcare utilization (readmission, emergency department visits, outpatient visits, physical therapy utilization), 90-day medical and acute postoperative complications, 90-day opioid exposure, and long-term fusion-related outcomes from 180 to 720 days, including pseudarthrosis and posterior cervical fusion. METHODS: Data were queried on March 9, 2026. Adults undergoing ACDF were identified and stratified by preoperative GLP-1 RA dose intensity. Exposure was defined by recorded GLP-1 RA prescription strength from 1 year to 1 week before the index ACDF procedure. Separate 1:1 propensity score matching was performed for each pairwise comparison. Outcomes were evaluated at 1-90 days for healthcare utilization, short-term complications, and opioid exposure, and at 180-720 days for long-term fusion-related outcomes. RESULTS: In the primary high-dose versus standard-dose comparison, 90-day healthcare utilization was similar, including readmission (11.4% vs. 10.0%; p=.327), emergency department visits (11.4% vs. 12.3%; p=.564), outpatient visits (49.8% vs. 52.1%; p=.328), and physical therapy utilization (42.0% vs. 44.0%; p=.397). Short-term complications were also similar, including composite medical complications (9.6% vs. 8.9%; p=.629), dysphagia (10.6% vs. 11.2%; p=.709), hematoma (6.8% vs. 6.3%; p=.638), dysphonia (1.8% vs. 1.6%; p=.721), and acute respiratory failure (2.3% vs. 1.7%; p=.406). Opioid exposure did not differ between cohorts (85.2% vs. 83.1%; p=.202). Long-term outcomes were likewise similar, including pseudarthrosis (4.0% vs. 3.8%; p=.822) and posterior cervical fusion (3.0% vs. 3.7%; p=.398). Compared with matched nonusers, both standard-dose and high-dose GLP-1 RA users had lower pseudarthrosis rates, although no additional long-term benefit was observed with higher-dose therapy. CONCLUSIONS: High-dose GLP-1 RA therapy was not associated with increased short-term healthcare utilization, postoperative complications, opioid exposure, or long-term fusion-related risk after ACDF compared with standard-dose therapy. These findings provide reassurance that higher-dose GLP-1 regimens do not appear to confer excess perioperative or fusion-related risk in this population.
-
What is the association between insulin dependence and the incidence of postoperative complications, perioperative glucose control, and five-year reoperation rates after total joint replacement?
AI summary of the abstract, unverified
- Retrospective single-centre cohort of 830 patients with diabetes undergoing primary THA or TKA from 2015 to 2022, split into insulin-dependent (351) and non-insulin-dependent (479) groups.
- The exposure was insulin dependence, compared with non-insulin-dependent diabetes, and outcomes were 90-day complications, perioperative glucose control, and mid-term reoperation.
- 90-day complications occurred in 35.9% of insulin-dependent patients versus 16.3% of others (p < 0.01), with an adjusted odds ratio of 2.81 (95% CI 1.98 to 3.98).
- Insulin dependence was also associated with poorer perioperative glucose control, while reoperation rates were similar between groups; the authors frame it as a risk marker beyond HbA1c.
Original abstract (PubMed)
AIMS: Diabetes mellitus (DM) is associated with adverse outcomes following total hip arthroplasty (THA) and total knee arthroplasty (TKA), yet optimal perioperative risk stratification remains unclear. This study evaluated the association of insulin dependence with: 1) 90-day complications; 2) perioperative glucose control; and 3) mid-term reoperations in diabetic patients undergoing primary THA and TKA. METHODS: We performed a retrospective, single-centre study of patients with DM undergoing primary THA or TKA between 2015 and 2022. Patients with preoperative glycated haemoglobin (HbA1c) ≥ 6.5 were categorized as insulin-dependent DM (IDDM) or insulin-independent DM (NIDDM). Demographic and clinical variables including preoperative haemoglobin A1C and oral DM medication usage were recorded. The primary outcome was 90-day complications. Secondary outcomes included mean and maximum perioperative glucose levels and reoperations. Multivariable logistic and linear regression analyses were used to evaluate association between insulin dependence and outcomes while adjusting for relevant confounders. RESULTS: A total of 830 patients were included: 351 (42.3%) with IDDM and 479 (57.7%) with NIDDM. Overall, 90-day complications were more common in the IDDM cohort (35.9% vs 16.3%, p < 0.01). Insulin dependence was associated with increased odds of 90-day complications (odds ratio 2.81, 95% CI 1.98 to 3.98). Male sex, metformin use, and glucagon-like peptide-1 receptor agonist use were associated with lower complication risk. Preoperative HbA1c was not independently associated with complications. Insulin dependence and preoperative haemoglobin A1C were associated with worse perioperative glucose control. Reoperation rates were similar between groups. CONCLUSION: Insulin dependence is an independent risk factor for 90-day complications and poorer perioperative glucose control, but not reoperation, following primary THA and TKA. These findings suggest insulin dependence is a clinically meaningful risk marker beyond glycaemic indices. Further investigation into optimization strategies to mitigate this perioperative risk is warranted.
-
The Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and Considerations.
AI summary of the abstract, unverified
- This is a narrative review appraising current evidence on perioperative GLP-1 receptor agonist use in total joint arthroplasty patients.
- It covers GLP-1 RA physiology, pharmacology, mechanisms, and commonly used agents, which are used for glycemic control and increasingly for weight loss.
- The review addresses complications, adverse effects, and separate considerations for anesthesiologists and TJA surgeons.
- It also summarizes clinical practice recommendations as of 2025, but the abstract reports no pooled numerical results.
Original abstract (PubMed)
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are used in diabetic patients for glycemic control. Yet, there has been a notable rise in their use for weight loss management in obese patients. This review critically appraises current evidence on perioperative implications of GLP-1 receptor agonists in TJA patients. The review discusses GLP-1 RA implications and use (physiology, pharmacology, pharmacodynamics, mechanisms of actions, and commonly used GLP-1 Ras), complications and adverse effects, considerations for the anesthesiologist, considerations for the TJA surgeon, and current clinical practice recommendations in 2025.
-
Association of GLP-1 Agonists With Postoperative Complications Following Knee Extensor Mechanism Repair: An Analysis of 1,092 Patients.
AI summary of the abstract, unverified
- Retrospective TriNetX database analysis of 1,092 patients undergoing quadriceps or patellar tendon repair, propensity-matched into two cohorts of 546.
- Exposure was preoperative GLP-1 receptor agonist use within one year of surgery, compared with patients without that use, followed to 90 days, 1 year, and 2 years.
- At 1 year, surgical site infection was lower with GLP-1 use (2.38% vs 5.31%; OR 0.435; P=.0118), as were wound complications (2.02% vs 5.31%; OR 0.367; P=.0037).
- No 90-day or revision surgery differences were found, and the authors suggest possible perioperative risk modulation as GLP-1 use grows.
Original abstract (PubMed)
BACKGROUND: Diabetes and obesity are recognized as risk factors for postoperative complications including increased surgical site infection (SSI) and reoperation in patients undergoing knee extensor mechanism repair. However, limited literature evaluates how preoperative glucagon-like peptide-1 (GLP-1) receptor agonist therapy may influence these outcomes. This study evaluated GLP-1 receptor agonist use as an independent risk factor for postoperative outcomes following knee extensor mechanism repair. MATERIALS AND METHODS: Patients who underwent quadriceps or patellar tendon repair from 2012 to 2025 were identified in the TriNetX database and stratified by GLP-1 agonist use within 1 year of surgery. One-to-one propensity score matching yielded 2 well-balanced cohorts (n = 546). Postoperative complications were assessed at 90 days, 1 year, and 2 years, and Kaplan-Meier survival analysis was performed. RESULTS: No significant 90-day postoperative differences were observed. At 1 year, patients using GLP-1 agonists demonstrated significantly lower rates of SSI (2.38% vs 5.31%; odds ratio [OR] = 0.435; P = .0118) and wound complications (2.02% vs 5.31%; OR = 0.367; P = .0037). Differences persisted at 2 years, with lower rates of SSI (2.75% vs 6.04%; OR = 0.439; P = .0079), wound complications (2.38% vs 6.04%; OR = 0.379; P = .0026), and acute kidney injury (9.71% vs 13.55%; OR = 0.686; P = .0474). No significant differences in revision surgery were found. Kaplan-Meier analysis demonstrated significant separation for SSI and wound complications beginning at 1 year. CONCLUSION: Preoperative GLP-1 receptor agonist therapy was associated with reduced postoperative SSI and wound complications following knee extensor mechanism repair. These findings suggest potential for perioperative risk modulation as GLP-1 use becomes increasingly prevalent in patients undergoing knee extensor mechanism repair.
-
Preoperative Weight Loss Before Total Joint Arthroplasty Using Novel Glucagon-Like Peptide-1 Agonists.
AI summary of the abstract, unverified
- This Level III study identified 6,482 patients who had primary hip or knee arthroplasty between 2019 and February 2023.
- The exposure was preoperative GLP-1 use, which rose from 2% of patients in 2019 to 5% in 2022.
- Among GLP-1 users, mean preoperative weight change was -9 pounds, and 19% lost at least 20 pounds; multivariable models showed no link to complications (P = .85).
- GLP-1 use was not associated with revisions, reoperations, or complications, and the 90-day emergency visit odds ratio was 1.5 (P = .07).
Original abstract (PubMed)
BACKGROUND: This study determined the prevalence of glucagon-like peptide-1 (GLP-1) use before total joint arthroplasty (TJA), measured weight loss of patients on GLP-1s, and evaluated if GLP-1s were associated with outcomes. METHODS: We identified 6482 patients (2990 hips; 3492 knees) who had primary TJAs between 2019 and February 2023. The mean age was 67 years, 50% were female, and 12% had a body mass index ≥40 kg/m2. Univariable and multivariable models evaluated outcomes. Mean follow-up was 3 years. RESULTS: The prevalence of GLP-1s before TJA was 3%, increasing from 2% in 2019 to 5% in 2022. The mean preoperative weight change on GLP-1s was -9 pounds (range, -110 to +36 pounds). Among patients taking GLP-1s, 19% lost ≥20 pounds prior to surgery, and the mean body mass index change was -1.4 kg/m2 (range, -16.3 to 6.2 kg/m2). In univariable analyses, GLP-1 use was not associated with revisions (P = .35), reoperations (P = .09), or complications (P = .23). In multivariable analyses, GLP-1s were not associated with revisions (P = .66), reoperations (P = .34), or complications (P = .85). There was no difference in the risk of a 90-day postoperative emergency department visit between those on GLP-1s vs not on those medications (odds ratio, 1.5; P = .07). CONCLUSIONS: The prevalence of preoperative GLP-1s before TJA increased from 2% in 2019 to 5% in 2022, and preoperative weight change on GLP-1s varied considerably. GLP-1s were not associated with decreased postoperative risks but investigational GLP-1s before TJA require further study. LEVEL OF EVIDENCE: Level III.
-
GLP-1 agonist use and lower rates of pseudarthrosis and dysphagia following anterior cervical discectomy and fusion surgery, with time-dependent effects.
AI summary of the abstract, unverified
- Database analysis of 2345 patients with GLP-1 RA exposure undergoing ACDF (CPT 22551) in TriNetX, 2014–2024, with 1:1 propensity-matched controls.
- Exposure timing was grouped as preoperative, perioperative, or postoperative, with a landmark approach for postoperative initiators to limit immortal time bias.
- Overall use was linked to less pseudarthrosis and dysphagia but not revision; the abstract reports no odds ratios, confidence intervals, or p values.
- Continuous perioperative use was associated with more dysphagia and revision but less sepsis, while postoperative initiation was linked to less pseudarthrosis, especially in patients with diabetes.
Original abstract (PubMed)
OBJECTIVE: Anterior cervical discectomy and fusion (ACDF) is among the most frequently performed spinal procedures in the US. Despite high success rates, complications such as pseudarthrosis, dysphagia, and revision surgery remain clinically significant, particularly in patients with diabetes mellitus (DM) and obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have demonstrated anti-inflammatory and bone-modulating properties in existing clinical and laboratory orthopedic research, yet their relationship to cervical fusion outcomes remains unclear, especially regarding therapy timing. The aim of this study was to evaluate the association between GLP-1 RA use and pseudarthrosis, dysphagia, and revision surgery, as well as perioperative complications, following ACDF surgery. METHODS: TriNetX, a global health research network, was queried (2014-2024) for patients undergoing ACDF surgery (CPT code 22551) with GLP-1 RA exposure. Subcohort analyses were conducted based on overall therapy timing (preoperative, perioperative, and postoperative) and further stratified by initiation and discontinuation timing. Postoperative initiators were analyzed using a landmark approach to mitigate immortal time bias. Each subcohort was 1:1 propensity score-matched to controls by age, sex, race, smoking, DM, BMI, and uremia. Ninety-day outcomes included deep vein thrombosis, pulmonary embolism, emergency department visit, inpatient hospitalization, sepsis, surgical site infection, and wound disruption. Two-year outcomes included pseudarthrosis, dysphagia, and revision surgery. Odds ratios with 95% confidence intervals were calculated using chi-square analysis. RESULTS: Among 2345 patients with GLP-1 RA exposure within 2 years after undergoing ACDF, overall use was associated with reduced pseudarthrosis and dysphagia, but not revision surgery. Preoperative GLP-1 RA use was associated with increased odds of dysphagia when discontinued > 12 months before surgery. Continuous perioperative use was associated with increased odds of dysphagia and revision surgery, as well as reduced odds of sepsis. Postoperative initiation was associated with reduced odds of pseudarthrosis and dysphagia in the overall subcohort, reduced odds of pseudarthrosis in patients with DM, and increased odds of dysphagia in those with multilevel fusion surgeries. CONCLUSIONS: GLP-1 RA use demonstrated timing-dependent associations with outcomes following ACDF surgery. Postoperative initiation of therapy was associated with reduced pseudarthrosis, particularly in patients with DM, and dysphagia, while continuous perioperative exposure increased the risk of dysphagia and revision. These findings suggest a potential role for temporally targeted GLP-1 RA therapy during postoperative healing. Prospective studies are required for validation and to determine causal relationships.
-
Prehospital glucagon-like peptide-1 receptor agonists are not associated with reduced inpatient opioid exposure but with shorter hospital length of stay after total joint arthroplasty.
AI summary of the abstract, unverified
- Retrospective cohort of 14,375 hip or knee arthroplasties, with 786 chronic GLP-1RA users propensity-matched 1:1 to 786 non-users.
- The exposure compared was chronic preoperative GLP-1RA therapy versus no GLP-1RA use.
- GLP-1RA use was not associated with lower inpatient opioid administration (adjusted difference -0.18; 95% CI -0.74 to 0.38; p=0.53) or with postoperative MME.
- GLP-1RA users had shorter length of stay (adjusted difference -10.41 hours; 95% CI -13.97 to -6.85; p<0.001), which the authors say needs prospective confirmation.
Original abstract (PubMed)
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been hypothesized to confer anti-inflammatory, antinociceptive, and anti-addictive benefits. We aimed to investigate their impact on acute perioperative pain and opioid use after total joint arthroplasty (TJA). METHODS: A retrospective cohort study analyzed 14,375 hip or knee arthroplasties performed between January 2018 and February 2026, which included 882 patients on chronic preoperative GLP-1RA therapy. Using 1:1 propensity-score matching without replacement, 786 GLP-1RA users were matched to 786 non-users (total n=1,572) based on demographics, surgery type, and chronic medication use. RESULTS: In the matched cohort, chronic GLP-1RA use was not associated with reduced inpatient opioid administration (adjusted difference -0.18; 95% CI, -0.74 to 0.38; p=0.53) or corrected postoperative morphine milligram equivalents (MME) (-2.79 MME; 95% CI, -6.95 to 1.37; p=0.19). When normalized to hospitalization time, the difference in inpatient opioid exposure was not statistically significant (+0.073 MME/hour; 95% CI, -0.003 to 0.149; p=0.059). Average visual analog scale (VAS) pain scores also showed no significant difference (-0.094; p=0.15). However, GLP-1RA users demonstrated a consistently shorter length of stay (LOS) (adjusted difference -10.41 hours; 95% CI, -13.97 to -6.85; p<0.001). CONCLUSIONS: Chronic preoperative GLP-1RA therapy was not associated with reduced inpatient opioid exposure or improved early postoperative pain control following TJA. Nevertheless, GLP-1RA use was consistently associated with shorter hospital LOS. Prospective studies are needed to determine whether this finding reflects improved recovery pathways or residual confounding and to evaluate the impact of GLP-1RAs on longer-term postoperative outcomes and opioid utilization.
-
A noninvasive 13C-mannitol breath test to monitor semaglutide treatment-induced delayed oral-cecal transit in mice.
AI summary of the abstract, unverified
- In this mouse study, the authors developed a noninvasive breath test of oral-cecal transit time using unanesthetized, freely moving animals.
- Orally given 13C-mannitol is metabolized by cecal microbiota to exhaled 13CO2, measured by indirect calorimetry with real-time 13C/12C ratio analysis.
- Pharmacological validation showed sensitivity to delayed transit, including a pronounced semaglutide-induced delay in obese mice; the abstract gives no effect sizes.
- The authors describe the method as high-throughput and longitudinal, improving rigor and reproducibility, and useful for GI physiology and drug studies.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are highly effective treatments for obesity and type 2 diabetes but are often associated with gastrointestinal side effects including delayed transit times through the gastrointestinal tract. We present a noninvasive breath test to measure oral-cecal transit time (OCTT) in mice that could be readily translated to clinical studies. Current methods for measuring OCTT are limited by invasiveness, terminal procedures, anesthesia, radioactive tracers, or stress-induced influence on the outcomes. Here we demonstrate that 13C-labeled mannitol is metabolized by murine cecal microbiota, producing measurable 13CO2 in exhaled breath. Using indirect calorimetry combined with real-time measurement of the 13C/12C ratio, this approach provides a highly granular, noninvasive method to measure OCTT in mice. This technique is performed in unrestrained freely moving animals while enabling high-throughput measurements performed longitudinally. The method improves experimental rigor and reproducibility and provides a valuable tool for studying gastrointestinal physiology and the effects of pharmacologic therapies.NEW & NOTEWORTHY A novel noninvasive assay uses orally administered 13C-mannitol, metabolized by cecal microbiota into exhaled 13CO2, to enable continuous, longitudinal measurement of oral-cecal transit time in unanesthetized, freely moving mice via indirect calorimetry with isotope ratio analysis. Pharmacological validation confirmed sensitivity to delayed transit, including a pronounced semaglutide-induced delay in obese mice that models a clinically relevant glucagon-like peptide-1 (GLP-1) receptor agonist adverse effect.
-
Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.
AI summary of the abstract, unverified
- This preclinical study used an LPS-induced inflammatory cognitive impairment model in mice, created by intracerebroventricular injection; the abstract does not report sample size.
- Mice received semaglutide alone or combined with the O-GlcNAc transferase inhibitor OSMI-1 and AKT-silencing adeno-associated viruses.
- Semaglutide reversed LPS-induced cognitive deficits and restored hippocampal O-GlcNAcylation, though the abstract reports no effect sizes or statistics.
- The authors conclude that semaglutide ameliorates perioperative neurocognitive disorder through AKT O-GlcNAcylation, AKT-mTOR activation, and downstream neuroprotection.
Original abstract (PubMed)
Perioperative neurocognitive disorder (PND) manifests as neurocognitive alterations induced by anesthesia and surgical stress. High-risk factors, including advanced age, obesity, diabetes, and preoperative neurological dysfunction, accelerate PND progression, with neuroinflammation serving as a core pathological mechanism throughout PND pathogenesis. Semaglutide regulates neuroinflammation in patients with diabetes and stroke, yet its role in PND remains undefined.A lipopolysaccharide (LPS)-induced inflammatory neurocognitive impairment mouse model was established via intracerebroventricular injection. Mice were treated with semaglutide alone or combined with the O-GlcNAc transferase inhibitor OSMI-1 and AKT-silencing adeno-associated viruses. Behavioral, biochemical and immunofluorescence assays were performed to evaluate cognitive function and molecular changes. Semaglutide significantly rescued LPS-induced cognitive deficits and restored hippocampal O-GlcNAcylation. Mechanistically, LPS inhibited AKT O-GlcNAc modification and AKT-mTOR pathway activity, facilitated mTOR-gephyrin binding, disrupted GABAAR distribution, aggravated neuronal apoptosis, and impaired synaptic plasticity. Semaglutide reversed these abnormalities by elevating AKT O-GlcNAcylation to activate the AKT-mTOR pathway, which triggered mTOR-gephyrin dissociation, restored synaptic GABAAR localization, attenuated neuronal damage, and rescued synaptic plasticity.Semaglutide ameliorates PND via AKT O-GlcNAcylation-mediated AKT-mTOR activation and subsequent neuroprotective effects.
-
Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes.
AI summary of the abstract, unverified
- This retrospective PearlDiver database study included 95,566 primary total shoulder arthroplasty patients, of whom 1,549 (1.62%) were GLP-1 receptor agonist users.
- GLP-1 users were compared with non-users after 10:1 exact matching on age, sex, Elixhauser index, diabetes, hypertension and overall obesity, with multivariable adjustment for remaining imbalances.
- After adjustment, no significant differences in medical or orthopaedic complications were found, while GLP-1 users had lower 90-day ED visit (OR 0.75; P < .01) and readmission (OR 0.71; P < .01) odds.
- The authors concluded GLP-1 use was not associated with worse outcomes and may be linked to lower healthcare utilisation, though obesity-class subgroup differences were not significant, likely due to small size.
Original abstract (PubMed)
PURPOSE: The increasing prevalence of Glucagon-like peptide-1 receptor agonists (GLP-1 RA) has raised concerns about their perioperative impact. Although database studies on GLP-1 RAs in total shoulder arthroplasty (TSA) have been published for diabetic and general TSA patients, results are conflicting, and the effects on patients across various obesity classes remain unexplored. This study aims to fill this gap. METHODS: The PearlDiver database was used to identify patients who underwent primary TSA, grouped by GLP-1 use, obesity status, and obesity class. Post-operative outcomes included 90-day readmission and emergency department (ED) visit rates, medical complications (including thromboembolic, infectious, and renal events), and orthopaedic complications (including revision, periprosthetic joint infection, and instability). Cohorts were matched 10:1 by exact matching on age, sex, Elixhauser comorbidity index, diabetes, hypertension and overall obesity status, and multivariable regression was used to adjust for comorbidities that remained imbalanced after matching. RESULTS: Among 95,566 patients, 1,549 (1.62%) were GLP-1 users. Initially, GLP-1 users exhibited higher pre-operative comorbidity burdens and rates of complications. However, after matching and multivariable adjustment for residual imbalance, no significant differences in medical or orthopaedic outcomes persisted. Notably, GLP-1 users demonstrated significantly lower odds of 90-day ED visits (OR 0.75; P < .01) and readmissions (OR 0.71; P < .01). Similar trends were observed within each individual obesity class, but none reached statistical significance, most likely reflecting the small size of these subgroups. CONCLUSION: After accounting for pre-operative comorbidities, our findings suggest that GLP-1 RA use is not associated with worse surgical outcomes in TSA patients and may be associated with lower post-operative healthcare utilisation, although residual confounding cannot be excluded. Further longitudinal studies are warranted to optimise perioperative GLP-1 RA administration.
-
Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.
AI summary of the abstract, unverified
- This bibliometric study analyzed the 50 most-cited Web of Science publications on GLP-1 receptor agonists in plastic, aesthetic, and reconstructive surgery.
- Nearly all of these articles appeared between 2023 and 2025, the literature was led by the USA, and authorship and institutions were widely spread with no clear hubs.
- Three themes emerged: aesthetic aging with facial soft-tissue change, perioperative management and safety, and body contouring after drug-induced weight loss.
- The authors describe the field as rapidly expanding but conceptually immature and largely descriptive, and they call for prospective, outcome-driven studies.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists are increasingly prescribed for medical weight management and have rapidly gained relevance within plastic, aesthetic, and reconstructive surgery. Their widespread use has raised questions regarding perioperative safety, tissue quality, body contouring outcomes, and aesthetic aging, prompting a growing but fragmented body of literature. METHODS: A bibliometric analysis was conducted using the Web of Science Core Collection to identify the 50 most cited publications addressing the intersection of glucagon-like peptide-1 receptor agonists and plastic, aesthetic, or reconstructive surgery. Bibliographic data were extracted and analyzed to evaluate publication trends, citation performance, contributing authors and institutions, journals, geographic distribution, and thematic structures. Keyword co-occurrence and network analyses were performed to identify dominant research domains and emerging topics. RESULTS: Nearly all highly cited articles were published between 2023 and 2025, reflecting the recent and abrupt emergence of this field. The literature was geographically dominated by the USA and was distributed across a wide range of institutions and authors, without clear investigative hubs. Thematic analysis revealed three principal domains: aesthetic aging and facial soft-tissue changes, perioperative management and safety considerations, and body contouring following pharmacologically induced weight loss. Keyword clustering demonstrated an evolving shift from metabolic and bariatric contexts toward aesthetic and procedural decision-making. CONCLUSIONS: The literature on glucagon-like peptide-1 receptor agonists in plastic surgery is rapidly expanding but remains conceptually immature and largely descriptive. This bibliometric analysis highlights current research priorities, influential contributions, and critical gaps, underscoring the need for prospective, outcome-driven studies to inform evidence-based surgical practice. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
-
Perioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study.
AI summary of the abstract, unverified
- This single-center retrospective cohort of 750 adults undergoing breast cancer surgery (January 2024 to August 2025) compared patients with and without GLP-1 RA use.
- Exposure was active GLP-1 RA use within 30 days before surgery, verified by pharmacy records, in 209 patients versus 541 unexposed.
- Adjusted analyses found no link to SSI (AOR 1.28, 95% CI 0.81-2.03), seroma (AOR 1.22, 95% CI 0.83-1.79), or grade II+ flap necrosis (AOR 1.41, 95% CI 0.83-2.40).
- The authors concluded that perioperative GLP-1 RA use was not independently associated with short-term complications, and that multicenter studies are needed to confirm safety.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for diabetes and obesity, but their perioperative safety in breast cancer surgery remains uncertain. This study evaluated the association between perioperative GLP-1 RA use and 30-day postoperative outcomes after breast cancer surgery. MATERIALS AND METHODS: This retrospective cohort study included adults undergoing breast cancer surgery at a tertiary center (January 2024-August 2025). Exposure was active GLP-1 RA use within 30 days preoperatively, verified via pharmacy records. The primary outcome was a composite 30-day surgical morbidity endpoint (surgical site infection [SSI], flap necrosis ≥ grade II, seroma requiring aspiration, or implant/expander loss). Secondary outcomes included venous thromboembolism (VTE), readmission, reoperation, and length of stay. Multivariable regression and inverse probability of treatment weighting (IPTW) addressed confounding. RESULTS: The analytic cohort comprised 750 patients (209 exposed, 541 unexposed; median age 51 years). Exposed patients had higher body mass index and diabetes prevalence. After adjustment, GLP-1 RA exposure was not associated with SSI (adjusted odds ratio [AOR] 1.28, 95% CI 0.81-2.03), seroma (AOR 1.22, 95% CI 0.83-1.79), or flap necrosis ≥ grade II (AOR 1.41, 95% CI 0.83-2.40). No secondary outcome showed independent association with exposure. Prolonged length of stay (≥ 3 days) occurred in 26.8% of patients overall and was attributable primarily to drain management requirements, extent of surgery, and metabolic comorbidity rather than GLP-1 RA exposure. CONCLUSION: Perioperative GLP-1 RA use was not independently associated with increased short-term complications after breast cancer surgery. Multicenter studies are needed to confirm safety across settings.
-
Temporal trends in patient demographics and postoperative outcomes in metabolic and bariatric surgery: a longitudinal analysis of the MBSAQIP database in the GLP-1 era.
AI summary of the abstract, unverified
- Database analysis of MBSAQIP centers in the United States comparing sleeve gastrectomy, bypass, and revision cases from 2015 and 2023.
- Calendar year is the exposure, framed as the GLP-1 receptor agonist era, though the abstract does not report GLP-1RA use directly.
- Primary BMI fell modestly (sleeve 45.3 to 44.9, bypass 46.6 to 45.9, both P<.001) while ASA scores were unchanged; revisional BMI, ASA, and comorbidities rose.
- The authors conclude that perioperative outcomes improved across all procedures, which they present as evidence of safety in the current GLP-1 era.
Original abstract (PubMed)
BACKGROUND: Utilization of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss has substantially increased in recent years, yet it remains unclear how the characteristics of patients pursuing metabolic and bariatric surgery (MBS) have evolved during this time. OBJECTIVES: This study compares patient characteristics and perioperative outcomes for primary and revisional MBS procedures from 2015 to 2023. SETTING: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) participating centers in the United States. METHODS: The MBSAQIP database was queried to identify all sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and revision/conversion procedures (revision). Preoperative body mass index (BMI), American Society of Anesthesiologists (ASA) score, number of comorbidities, and perioperative outcomes were analyzed longitudinally. RESULTS: The number of procedures increased from 2015 to 2023 (SG: 91,553 vs 129,475; RYGB: 43,143 vs 60,312; revision: 23,138 vs 26,478). For primary MBS, average BMI decreased (SG: 45.3 [8.3] vs 44.9 [7.8], P < .001; RYGB: 46.6 [8.6] vs 45.9 [8.0], P < .001), while ASA scores did not change. Number of comorbidities decreased for SG (1.6 [1.4] vs 1.5 [1.4], P < .001) but remained the same for RYGB. For revisional procedures, average BMI (39.4 [9.7] vs 41.1 [8.5]; P < .001), ASA score (2.7 [.5] vs 2.8 [.5], P < .001), and number of comorbidities (2.3 [1.4] vs 2.6 [1.4], P < .001) increased. Perioperative outcomes improved for all procedures. CONCLUSIONS: Primary MBS is now being performed in patients with lower average BMI, while revisional cases are performed in patients with higher BMI and more comorbid conditions. Despite this, perioperative outcomes have improved, highlighting the safety of modern MBS in the modern GLP-1 era.
-
Glucagon-like Peptide-1 as a Promising Marker of Postoperative Intestinal Ischemia After Abdominal Aortic Surgery.
AI summary of the abstract, unverified
- Prospective single-center cohort of 80 patients undergoing elective abdominal aortic surgery, with serum GLP-1 measured at eight perioperative time points.
- Intestinal ischemia was confirmed by contrast-enhanced MRI or surgery, and six patients developed it; GLP-1 was compared between those with and without ischemia.
- Patients with ischemia had significantly higher GLP-1 at all postoperative time points (P < 0.02), with AUC 0.993 at 24 hours and 0.919 at 6 hours after declamping.
- The authors conclude that elevated GLP-1 shows high specificity for ischemia, independent of diabetes or age, and is a promising predictive biomarker.
Original abstract (PubMed)
BACKGROUND: Acute intestinal ischemia is a severe postoperative complication of abdominal aortic surgery, and delayed diagnosis markedly limits therapeutic options. At present, no reliable biochemical marker for early detection is available. This study assesses whether perioperative changes in glucagon-like peptide-1 (GLP-1) may serve as an early biomarker of postoperative intestinal ischemia. METHODS: This prospective single-center cohort study enrolled 80 patients undergoing elective abdominal aortic surgery. Total serum GLP-1 concentrations were measured at 8 perioperative time points spanning the preoperative, intraoperative, and postoperative periods. Intestinal ischemia was diagnosed using contrast-enhanced magnetic resonance imaging or surgical confirmation. RESULTS: The perioperative time course of GLP-1 was similar across all patients, with peak concentrations consistently observed 24 hr after complete declamping during vascular reconstruction. Six patients developed intestinal ischemia; these individuals exhibited significantly higher GLP-1 levels at all postoperative time points than patients without ischemia (P < 0.02). GLP-1 demonstrated the highest predictive ability at 24 hr after complete declamping (area under the receiver operating characteristic curve [AUC] 0.993); similarly, measurements obtained at 6 hr after complete declamping exhibited excellent predictive performance (AUC 0.919). CONCLUSION: Perioperative elevation of GLP-1 demonstrates high specificity for intestinal ischemia, independent of diabetes mellitus or age. Serum GLP-1 concentrations show promise as reliable predictive biomarkers for postoperative intestinal ischemia, with the best diagnostic accuracy observed at 6 and 24 hr after complete declamping during vascular reconstruction.
-
Perioperative and Renal Outcomes After Nephrectomy in Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists: A Pilot Study.
AI summary of the abstract, unverified
- This retrospective national claims study matched 980 patients on GLP-1RAs 1:1 to 980 controls, all with BMI ≥27 kg/m² undergoing nephrectomy for renal neoplasms.
- The exposure was GLP-1RA therapy within 180 days of surgery, compared with matched patients not receiving it, with outcomes assessed at 30 and 90 days.
- GLP-1RA use was associated with lower 90-day AKI (OR 0.76; P = .031), lower MAKE (OR 0.56; P = .004), and lower 30-day readmission (OR 0.72; P = .011).
- The authors conclude that GLP-1RAs may mitigate postoperative risk without increasing gastrointestinal, respiratory, or systemic morbidity.
Original abstract (PubMed)
INTRODUCTION: Patients with elevated BMI undergoing nephrectomy are at increased risk of acute kidney injury (AKI) and perioperative complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may confer renal-protective and anti-inflammatory effects while reducing perinephric adiposity. Thus, we aimed to determine whether GLP-1RA use is associated with fewer perioperative complications following nephrectomy. METHODS: We conducted a retrospective, national claims analysis of patients undergoing nephrectomy from June 2021 to October 2025. Patients with BMI ≥ 27 kg/m2 undergoing nephrectomy for renal neoplasms were included. Patients receiving GLP-1RA therapy within 180 days of surgery were 1:1 propensity matched by demographics (age, sex, race), comorbidities (body mass index, chronic kidney disease, hypertension, hyperlipidemia, diabetes mellitus, tobacco use), and metformin/sodium-glucose cotransporter-2 inhibitor use. Outcomes included 30-day and 90-day adverse events overall and stratified by partial and radical nephrectomy. RESULTS: After 1:1 matching, 980 individuals on GLP-1RAs were well balanced with 980 controls from a pool of 36,382 eligible patients. At 30 days, GLP-1RA use was associated with lower rate of hospital readmission (odds ratio [OR] = 0.72; P = .011). At 90 days, GLP-1RA users had a reduced incidence of venous thromboembolism (OR = 0.62; P = .035) and readmission (OR = 0.62; P < .001). Those on GLP-1RA therapy had significantly lower odds of 90-day AKI (OR = 0.76; P = .031) and major adverse kidney events (MAKEs; OR = 0.56; P = .004). MAKE was significantly lower for partial (OR = 0.45; P = .0024) and radical (OR = 0.54; P = .0014) nephrectomy. CONCLUSIONS: Preoperative GLP-1RA use appeared to reduce rates of AKI, MAKE, and 30/90-day readmission among patients undergoing nephrectomy. These findings suggest GLP-1RAs may mitigate postoperative risk without increasing gastrointestinal, respiratory, or systemic morbidity.
-
Impact of GLP-1 Receptor Agonist Use on Total Knee Arthroplasty Outcomes in Metformin-Treated Diabetic Patients With and Without Comorbid Obesity: A Propensity-Matched Analysis.
AI summary of the abstract, unverified
- Database study of metformin-treated T2DM patients undergoing primary TKA, split by obesity status and propensity matched 1:1.
- The exposure was GLP-1RA use within three months of surgery, compared with patients not using GLP-1RAs.
- Obesity subgroup: GLP-1RA use was linked to less anemia (OR 0.714; P = 0.001), 90-day readmission (OR 0.776; P = 0.001), and two-year aseptic loosening (OR 0.498; P = 0.037).
- Nonobese patients had lower 90-day readmission (OR 0.514; P = 0.004) and ED visits (OR 0.649; P = 0.024); authors report reduced resource use irrespective of obesity.
Original abstract (PubMed)
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been linked to improved outcomes following total knee arthroplasty (TKA). However, it remains unclear whether the observed benefits are attributable to weight loss, glycemic control, or first-line type 2 diabetes mellitus (T2DM) medications such as metformin. This study aimed to evaluate the impact of perioperative GLP-1RA use on TKA outcomes in T2DM patients stratified by obesity status. METHODS: The TriNetX Global Collaborative Network was queried using relevant Current Procedural Terminology and ICD-10 codes for metformin-treated T2DM patients aged 18 years or older undergoing primary TKA. Patients were divided into two groups based on obesity status and further stratified based on GLP-1RA use within three months of surgery. The groups were propensity matched (1:1) based on age, sex, body mass index (BMI), HbA1c, and comorbidities. Surgical outcomes, medical complications, and resource utilization were assessed at 90 days and 1 year. Surgical outcomes and revision rates were also assessed at two years. RESULTS: In obese patients (n = 8,170), GLP-1RA use was associated with notable reductions in postoperative anemia (odds ratio [OR] 0.714; P = 0.001), acute kidney injury (OR 0.755; P = 0.021), 90-day readmission (OR 0.776; P = 0.001), emergency department (ED) visits (OR 0.836; P = 0.008), and aseptic loosening at two years (OR 0.498; P = 0.037). These patients also demonstrated greater postoperative reductions in BMI and HbA1c. In nonobese patients (n = 1,328), GLP-1RA use was similarly associated with lower rates of 90-day readmission (OR 0.514; P = 0.004) and ED visits (OR 0.649; P = 0.024), although no notable differences in other outcomes were observed. CONCLUSION: Among metformin-treated T2DM patients undergoing TKA, GLP-1RA use was associated with reduced resource utilization irrespective of obesity. However, additional reductions in medical complications and aseptic loosening were observed in the obese group, suggesting a potential synergistic effect between weight loss and glycemic control. These findings highlight the effectiveness of GLP-1RAs in optimizing high-risk candidates undergoing TKA.
-
Association of GLP-1 inhibitors with cardiovascular outcomes in patients undergoing coronary artery bypass surgery.
AI summary of the abstract, unverified
- Retrospective review of a prospectively maintained cardiac surgery database covering nonemergent isolated CABG patients from 2010 to 2024, with 4170 having complete medication data.
- Preoperative GLP-1 users (165 patients, 3.9%) were compared with nonusers using multivariable Cox models for all-cause mortality, MACCE, and 30-day mortality.
- After adjustment, no significant difference in all-cause mortality or MACCE was found between the groups.
- GLP-1 use was associated with less new-onset postoperative atrial fibrillation (14% vs 22%; P = .02), which the authors say warrants further study.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated cardiovascular benefit in patients with diabetes and obesity. Patients undergoing coronary artery bypass grafting (CABG) often have similar cardiovascular risk profiles. Therefore, this study sought to investigate the impact of preoperative GLP-1 use in patients undergoing CABG. METHODS: A retrospective review of a prospectively maintained cardiac surgery database was conducted. Patients undergoing a nonemergent isolated CABG between 2010 and 2024 were stratified by GLP-1 users and nonusers. Multivariable Cox proportional hazards regression models were used to assess the risk of all-cause mortality, major adverse cardiovascular and cerebral events (MACCE), and short-term 30-day mortality. Variables for multivariable adjustment were selected by variable importance of random forest models. RESULTS: A total of 11,389 patients underwent isolated CABG, of whom 4170 had complete medication data. Among these, 165 patients (3.9%) were on GLP-1 for a median of 353 days. GLP-1 users were younger and more likely to be female, diabetic, hypertensive, and to have a higher body mass index. GLP-1 users had a longer intensive care unit length of stay, although the overall length of stay was similar in the 2 groups. In adjusted analysis, no significant difference in all-cause mortality or MACCE was found between groups. Notably, GLP-1 use was associated with a significantly lower incidence of new-onset postoperative atrial fibrillation (14% vs 22%; P = .02). CONCLUSIONS: Preoperative GLP-1 use in CABG patients was not associated with an increased risk of mortality or MACCE. GLP-1 use was associated with reduced postoperative atrial fibrillation, which warrants further investigation of GLP-1's potential perioperative benefits in larger studies.
-
Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis.
AI summary of the abstract, unverified
- A retrospective propensity-matched cohort from the TriNetX database examined 30-day wound complications after panniculectomy, abdominoplasty, or breast reduction.
- Patients on GLP-1 receptor agonists were compared with non-users, with diabetes, vascular disease, cancer, and smoking excluded.
- Matched complication rates were 4.7% vs 2.7% for panniculectomy (P = 0.05), 9.8% vs 3.6% for abdominoplasty (P = 0.001), and 2.6% vs 1.3% for breast reduction (P = 0.035).
- The authors conclude GLP-1 RA use was associated with more surgical site complications across all procedures and support preoperative counseling and perioperative planning.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained Food and Drug Administration approval for management of type 2 diabetes. However, they have been increasingly used for their weight loss side effect profile. Surgical site wound complications have been observed in patients using these medications (although with a low incidence rate). Given the paucity of literature on weight loss medications and their implications in plastic surgery, this study evaluates the impact of weight loss medication use on postoperative surgical site outcomes in patients undergoing common plastic and reconstructive procedures. METHODS: The TriNetX National Health Research database was queried to identify patients undergoing panniculectomy, abdominoplasty, or breast reduction. Patients with diabetes; peripheral vascular diseases; nutritional, metabolic, or endocrine diseases; a history of cancer; or smoking were excluded. Propensity matching analysis was performed to balance the cohorts. Postoperative outcomes, specifically surgical wound infections, breakdown, or dehiscence within 30 days after the procedure, were assessed based on GLP-1 RA use status. RESULTS: The risk of surgical site wound healing complications in patients taking GLP-1 RAs compared with those not on these medications was statistically significantly higher before cohort matching as well as after matching. Matched cohort results were as follows: 4.7% versus 2.7% for panniculectomy ( P = 0.05), 9.8% versus 3.6% for abdominoplasty ( P = 0.001), and 2.6% versus 1.3% for breast reduction ( P = 0.035), respectively. CONCLUSIONS: Use of GLP-1 RAs was associated with higher rates of surgical site complications across all evaluated procedures. This underscores the necessity of patient counseling regarding the implications of these weight loss medications before surgery, along with the potential need for a strategic perioperative management plan to enhance surgical outcomes.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
- No matching papers in this section with the selected filters.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.